AAV Manufacturing Taysha's emphasis on AAV9-based gene therapies and the TSHA-102 Rett program creates demand for scalable vector supply, process development, and GMP manufacturing partnerships. Target CMOs with proven AAV production capabilities and CNS-targeted vector expertise to support early-phase and potential future trials.

Regulatory Acceleration RMAT designation and FDA engagement position TSHA-102 for accelerated development, creating opportunities for regulatory consulting, orphan-drug strategy, and global submissions partnerships with firms that can support expedited timelines and risk-sharing in clinical development.

Rare Disease Partnerships Rett syndrome focus presents collaboration opportunities with patient advocacy groups, centers of excellence, and academic consortia to support trial recruitment, natural history data collection, and biomarker validation, offering channels for CRO and biotech partners to co-develop and accelerate programs.

Trial Recruitment With a clinical-stage profile and US footprint, Taysha can leverage digital engagement and site-network services to accelerate patient enrollment for Rett trials. Partnerships with patient registries, digital marketing providers, and site-management platforms can reduce cycle times and de-risk timelines.

Conference Outreach Upcoming appearances at major gene-therapy conferences signal a strong channel for deal-flow, partner discovery, and investor-analyst briefings. BD teams can convert conference momentum into licensing, collaboration, or manufacturing services agreements around TSHA-102 and future CNS programs.